• Vacuolin-1: Lysosomal Exocytosis Inhibitor Workflow

  2026-08-18

  Vacuolin-1 provides a selective way to interrogate Ca2+-dependent lysosome–plasma membrane fusion in secretion, membrane repair, and trafficking assays. This practical guide connects β-hexosaminidase release and Lamp-1 surface exposure measurements with disease-oriented questions raised by MPS IVA cartilage research.

• Norovirus Co-opts NINJ1 for Selective NS1 Secretion

  2026-08-18

  A 2025 Science Advances study identifies NINJ1 as an essential component of murine norovirus NS1 secretion and shows that caspase-3 processing enables this unconventional release pathway. The work links viral replication-site organization, NINJ1 oligomerization, and selective cargo interaction while demonstrating that caspase-3 activity is required for efficient oral infection in mice.

• Cy5 amine (non-sulfonated): Protocol Guide

  2026-08-17

  Cy5 amine (non-sulfonated), SKU A8143, is an amine-functionalized cyanine reagent for covalent fluorescent labeling when the reaction partner provides a compatible activated ester, activated carboxyl group, or epoxide. Because it is insoluble in water, it should be prepared in DMSO or ethanol and used with solvent and precipitation controls rather than added directly as an aqueous labeling reagent.

• Hesperadin Workflow for Aurora B Research

  2026-08-17

  Hesperadin provides a mechanism-focused way to connect Aurora B inhibition with histone H3 Ser-10 loss, chromosome-segregation defects, and polyploidization. This workflow also shows how to pair Aurora B perturbation with checkpoint-disassembly assays inspired by the p31comet–TRIP13 study, while avoiding overinterpretation of overlapping mitotic phenotypes.

• GPR30 in Spinal CCK+ Neurons and Neuropathic Pain

  2026-08-16

  The reference study identifies GPR30 in spinal CCK-positive excitatory neurons as a cell-type-specific contributor to nerve-injury-induced allodynia. By combining synaptic physiology, circuit tracing, behavioral testing, and chemogenetic manipulation, it connects GPR30-dependent AMPA signaling with a primary somatosensory cortex to spinal dorsal horn pathway.

• From HCC Biology to Better Spatial Evidence

  2026-08-15

  Translational researchers increasingly need spatially resolved evidence to connect metabolic mechanisms with tumor behavior. This thought-leadership article examines how Cy5 tyramide signal amplification can strengthen validation of the miR-3180–SCD1–CD36 axis in hepatocellular carcinoma while clarifying assay maturity, controls, and strategic limitations.

• GlycoRNA–RBP Domains on the Cell Surface

  2026-08-14

  The reference preprint reports that cell-surface RNA-binding proteins and glycoRNAs assemble into nanoclusters that support entry of the cell-penetrating peptide TAT. Its perturbation experiments connect extracellular RNA, surface organization, and peptide internalization, expanding models of how the plasma membrane communicates with the extracellular environment.

• Influenza Hemagglutinin (HA) Peptide for IDH1 Studies

  2026-08-14

  Use this high-purity HA tag peptide to recover HA-fusion proteins under gentle, antibody-compatible conditions and to compare IDH1 variants in interaction and purification assays. The workflow connects competitive HA elution with the reference study’s chemoproteomic investigation of IDH1-R132H autopalmitoylation while clearly separating affinity purification from lipid-modification measurement.

• (R)-MG132 in Proteasome Mechanism Studies

  2026-08-13

  (R)-MG132 is a functionally inactive MG-132 enantiomer that strengthens proteasome inhibition validation. This article explains how to use it as a causal control when studying HNRNPU lactylation, PHGDH regulation, and cancer metabolism.

• Oseltamivir acid: Applied Research Workflows

  2026-08-13

  Oseltamivir acid supports a practical workflow that connects neuraminidase inhibition with influenza virus replication inhibition, resistance profiling, and exploratory oncology assays. This guide covers formulation, infection-model design, combination testing, translational interpretation, and troubleshooting for reproducible influenza antiviral research.

• G-1: Selective GPR30 Agonist Workflows

  2026-08-12

  G-1 enables controlled activation of GPR30/GPER1 in calcium, migration, cardiovascular, and spinal-neuron assays. This workflow-focused guide connects receptor pharmacology with practical dosing, controls, troubleshooting, and interpretation limits.

• Drug Response Metrics in Cancer In Vitro

  2026-08-12

  Hannah Schwartz’s dissertation separates relative viability from fractional viability to distinguish growth inhibition from actual cell killing. Its central implication is that anticancer responses should be interpreted across both dimensions and across time, rather than treating a single viability measurement as a complete description of drug activity.

• Z-DEVD-FMK in DR5 Apoptosis Assays

  2026-08-11

  Z-DEVD-FMK is more than a caspase-3 inhibitor: its activity across executioner caspases and calpain creates a powerful, but nuanced, perturbation tool. This article shows how to apply it to DR5–PD-L1 apoptosis assays without confusing pathway blockade with mechanistic proof.

• Cabozantinib (XL184) in RCC Signaling Research

  2026-08-11

  Cabozantinib, also called XL184, is a multi-target receptor tyrosine kinase inhibitor with VEGFR2, MET, RET, and AXL activity. Evidence from kinase assays, tumor models, and renal cell carcinoma phosphoproteomics supports its use for studying angiogenesis, tumor signaling, and chronic drug adaptation.

• Oseltamivir acid: Influenza Research Workflows

  2026-08-10

  Build reproducible neuraminidase, viral replication, and oncology assays with Oseltamivir acid, while controlling solubility, vehicle effects, and resistance-related variability. This guide translates product-specific evidence and a humanized-mouse pharmacokinetic study into practical assay decisions for influenza antiviral research.

16919 records 1/1128 page Next 12345 下5页 Last page